CJC-1295 Purity: HPLC & MS Verification
Achieving rigorous analytical precision in preclinical growth hormone signaling research requires verified high-purity peptides. CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analog evaluated in laboratory models for its sustained stimulation of GH and downstream insulin-like growth factor 1 (IGF-1) expression. This technical guide outlines the analytical protocols, purity metrics, and quality controls necessary to eliminate experimental artifacts in CJC-1295 research.
Quick answer
Achieving rigorous analytical precision in preclinical growth hormone signaling research requires verified high-purity peptides. CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analog evaluated in laboratory models for its sustained stimulation of GH and downstream insulin-like growth factor 1 (IGF-1) expression. This technical guide outlines the analytical protocols, purity metrics, and quality controls necessary to eliminate experimental artifacts in CJC-1295 research.
Key takeaways
- [CJC-1295](/research-peptides/cjc-1295-no-dac) is a modified 29-amino acid peptide analog of endogenous growth-hormone-releasing hormone (GHRH 1-29).
- In cell culture systems and animal models, minor impurities within synthetic peptide samples can lead to false-positive or false-negative experimental outcomes.
- Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is the primary analytical method used to measure the chemical purity of [CJC-1295](/research-peptides/cjc-1295-no-dac).
- While HPLC confirms chemical separation and relative abundance, Mass Spectrometry (MS) provides definitive confirmation of molecular weight and sequence identity.
Molecular Profile and Structural Mechanics of CJC-1295
CJC-1295 is a modified 29-amino acid peptide analog of endogenous growth-hormone-releasing hormone (GHRH 1-29). In laboratory settings, GHRH peptides function by binding to the GHRH receptor (GHRHR) on pituitary somatotropes, stimulating signal transduction cascades that result in pulsatile growth hormone synthesis and secretion. The native GHRH sequence suffers from rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV), yielding a short biological half-life in physiological media.
To mitigate rapid degradation, CJC-1295 incorporates four specific amino acid substitutions (Tyr1, Ala2, Asp3, and Asn8 modifications) that confer enhanced resistance to enzymatic inactivation. In addition to this tetrasubstituted modified GRF 1-29 sequence, CJC-1295 can be synthesized with or without a Drug Affinity Complex (DAC) reactive group. When evaluated in preclinical models, CJC-1295 sustains baseline GH concentrations and elevates circulating downstream IGF-1 levels, serving as a primary model for tissue repair, cellular regeneration, and metabolic research. Maintaining strict structural integrity during synthesis is critical to ensuring receptor binding affinity in experimental assays.
The Impact of Peptide Purity on GHRH Signaling Assays
In cell culture systems and animal models, minor impurities within synthetic peptide samples can lead to false-positive or false-negative experimental outcomes. When evaluating a GHRH analog, chemical impurities such as truncated sequences, deletion peptides, stereoisomers, or residual organic solvents alter binding dynamics and receptor kinetics. These uncharacterized contaminants can compete with the primary peptide for receptor sites or cause non-specific cellular toxicity.
For reproducible data, investigators rely on strict peptide purity standards. A standard threshold of >98% or >99% purity ensures that observed pharmacological responses—such as intracellular cAMP accumulation or downstream cellular proliferation—are directly attributable to CJC-1295 rather than background synthetic artifacts. High-purity reference materials prevent batch-to-batch variation from skewing longitudinal tissue repair studies.
High-Performance Liquid Chromatography (HPLC) Analysis
Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is the primary analytical method used to measure the chemical purity of CJC-1295. RP-HPLC separates the target peptide from related impurities based on hydrophobic interactions with a stationary phase column, typically a C18 silica matrix. A gradient elution consisting of water, acetonitrile, and trifluoroacetic acid (TFA) as a ion-pairing reagent isolates the primary peak from structurally closely related compounds.
The resulting UV chromatogram (measured at 214 nm or 220 nm to detect peptide bonds) displays a sharp, dominant absorption peak corresponding to CJC-1295. Purity is expressed as the area under the curve (AUC) percentage of the target peak relative to the total integrated area of all detected peaks. High-grade research lots of CJC-1295 No DAC must display an HPLC purity of ≥98.0%, with zero single impurity exceeding 1.0% of the total integrated profile.
Mass Spectrometry (MS) Verification and Sequence Validation
While HPLC confirms chemical separation and relative abundance, Mass Spectrometry (MS) provides definitive confirmation of molecular weight and sequence identity. Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) or Electrospray Ionization Mass Spectrometry (ESI-MS) measures the mass-to-charge ratio (m/z) of the ionised CJC-1295 molecule.
The theoretical monoisotopic mass of tetrasubstituted modified GRF 1-29 (CJC-1295 without DAC) is approximately 3367.9 Da. Mass spectrometry confirms that the dominant molecular ion peak corresponds precisely to this expected molecular mass, ruling out incorrect amino acid additions, missing residues, or un-deprotected side-chain functional groups. Combining HPLC purity metrics with MS mass identity verification guarantees that the material matches target specifications prior to inclusion in sensitive in vitro or in vivo studies accessible through our research library hub.
Bacterial Endotoxin Limits and Environmental Quality Controls
For animal models and sensitive primary cell cultures, chemical purity alone is insufficient. Synthetic peptides can harbor pyrogenic contaminants, such as lipopolysaccharides (LPS) derived from Gram-negative bacteria, introduced during handling or purification. In vitro data indicate that even nanomolar levels of endotoxins trigger inflammatory pathways (including NF-κB activation and cytokine release) that invalidate tissue repair or immune response experiments.
PX1 Research enforces stringent regulatory thresholds using the Limulus Amebocyte Lysate (LAL) assay to quantify endotoxins. Every lot of CJC-1295 is verified to contain <0.05 EU/mg, protecting cellular protocols from pyrogen-induced baseline distortion. Detailed protocols regarding endotoxin limits in research peptides are essential for maintaining rigorous control environments across all biological evaluations.
Comparative Analysis: CJC-1295 vs. Sermorelin, Tesamorelin, and Ipamorelin
When designing GHRH and secretagogue studies, researchers frequently compare CJC-1295 against other compounds in the same functional class. Unlike Sermorelin—the unmodified native 29-amino-acid segment of GHRH with a rapid clearance rate—CJC-1295 contains four specific substitution sites designed to extend plasma half-life and sustain steady-state GH levels. Compared to Tesamorelin, a GHRH analog featuring a trans-3-hexenoic acid modification specifically evaluated for lipid metabolism models, CJC-1295 maintains a distinct pharmacokinetic profile without the N-terminal hexenoyl group.
Additionally, CJC-1295 operates upstream through the GHRH receptor, whereas ghrelin receptor agonists like Ipamorelin act via the growth hormone secretagogue receptor (GHSR-1a). Preclinical models often combine high-purity CJC-1295 and Ipamorelin to investigate synergistic receptor cross-talk and dual pathway-mediated somatotrope activation. Ensuring high purity across all combined compounds is vital to prevent confounding synergistic artifacts.
Impact of Synthetic By-Products and Truncated Sequences
During solid-phase peptide synthesis (SPPS), coupling inefficiencies can result in truncated sequences (e.g., des-amino acid peptides) or deletion sequences missing one or more internal amino acids. Because these by-products share similar physical properties with the full-length CJC-1295 sequence, basic purification methods may fail to remove them.
In preclinical bioassays, truncated GHRH fragments can act as partial agonists or competitive antagonists, attenuating full receptor activation and artificially blunting the measured growth hormone response. Furthermore, racemized amino acids (D-enantiomers formed during coupling steps) alter the tertiary conformation of the peptide, diminishing its receptor binding kinetics. Rigorous preparative HPLC purification and analytical batch validation prevent these non-functional sequences from compromising biological measurements.
Reconstitution, Counter-Ion Dynamics, and Lab Handling
The physical stability of synthesized CJC-1295 relies on proper lyophilizate formulation and reconstitution technique. Standard solid-phase synthesis utilizes trifluoroacetic acid (TFA) during cleavage, leaving residual TFA counter-ions associated with basic amino acid side chains (such as Lys and Arg). For specialized cell cultures sensitive to pH shifts or halide toxicity, researchers may evaluate alternative counter-ion forms or account for net peptide content when preparing molar concentrations.
To preserve chemical stability, lyophilized CJC-1295 should be stored at -20°C or -80°C in a desiccated environment. Reconstitution should be performed using sterile, bacteriostatic, or deaerated laboratory-grade buffers (such as PBS or sterile water) depending on experimental requirements. Aliquoting reconstituted solutions minimizes freeze-thaw cycles, preventing mechanical shear and peptide aggregation that degrade functional concentration over time.
PX1 Research Quality Assurance and Institutional Sourcing
PX1 Research provides institutional laboratories and independent researchers with reference-grade research compounds manufactured under strict Quality Management Systems. Our CJC-1295 is USA-synthesized in state-of-the-art, GMP-compliant facilities and thoroughly evaluated by an independent ISO 17025 accredited laboratory.
Every batch undergoes comprehensive characterization—including full-spectrum HPLC chromatograms, ESI/MALDI mass spectrum analysis, counter-ion determination, moisture content analysis, and micro-LAL endotoxin testing. Institutional investigators establishing high-volume research pipelines can access volume tier agreements via our wholesale lab account portal, backed by same-day shipping from our dual distribution hubs in California and Arizona.
Frequently Asked Questions
How is CJC-1295 purity verified at PX1 Research?
CJC-1295 purity is verified through reverse-phase high-performance liquid chromatography (RP-HPLC) coupled with mass spectrometry (MS). HPLC isolates individual chemical species to determine purity percentage based on peak area, while MS confirms exact molecular mass and sequence identity.
What is the recommended HPLC purity threshold for CJC-1295 in cell culture studies?
For cell culture and in vitro bioassays, a minimum purity threshold of >98.0% (preferably ≥99.0%) is recommended to prevent truncated amino acid sequences or chemical impurities from interfering with GHRH receptor signaling.
What is the main difference between CJC-1295 with DAC and CJC-1295 without DAC?
CJC-1295 with DAC includes a Drug Affinity Complex reactive group that covalently binds to circulating albumin in animal models, significantly extending its half-life. CJC-1295 without DAC (also known as Modified GRF 1-29) lacks this reactive moiety, resulting in a shorter, pulsatile pharmacokinetic profile.
Why is endotoxin testing critical for CJC-1295 research lots?
Bacterial endotoxins (lipopolysaccharides) induce non-specific inflammatory responses in cell culture and animal models. Low endotoxin levels (<0.05 EU/mg) ensure that cellular signaling changes are driven by GHRH activation rather than immune pathway activation.
How should CJC-1295 be stored upon arrival in the laboratory?
Lyophilized CJC-1295 should be stored at -20°C or -80°C in a dry, dark environment. Once reconstituted in an appropriate sterile laboratory buffer, solutions should be aliquoted and kept frozen to avoid multiple freeze-thaw cycles.
What documentation accompanies CJC-1295 orders from PX1 Research?
Every lot of CJC-1295 includes a lot-specific Certificate of Analysis (COA) detailing the HPLC chromatogram, MS spectrum, purity percentage, verified mass, and endotoxin assay results from an ISO 17025 accredited analytical facility.
How do truncated sequence impurities affect growth hormone secretion assays?
Truncated sequences share partial structural homology with CJC-1295 and can act as competitive antagonists or partial agonists at the GHRH receptor, leading to inaccurate baseline measurements in secretion assays.
Can PX1 Research provide bulk quantities of CJC-1295 for ongoing institutional research?
Yes, PX1 Research offers institutional supply agreements and bulk ordering options through our wholesale portal, offering batch-reserved lots to guarantee longitudinal experimental consistency.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.